Author | Year | Double blinded | Dose (mg/kg/day) | Course length (day) | Start age | No of patients | Characteristics | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Durandet al 34 | 1995 | No | 0.5 (3), 0.25 (3), 0.1 (3) | 7 | 7–14 d | 43 | 501–1500 g; 24–32 w; MV at 7–14 d; surfactant 26% in dex and 65% in control received steroids | |||||||
Brozanski et al 35 | 1995 | Yes | 0.5 (3) every 10 days, until*36 w PMA or no O2 therapy | Until 36 w PMA | 7 d | 78 | <1500 g; stratified <1000, >1001; surfactant; MV No crossover | |||||||
Kari et al 36 | 1993 | Yes | 0.5 (7) | 7 | 10 d | 41 | <1500 g; >24 w; MV at 10 days; only 3 patients in in dex group and 1 control received surfactant 33% of controls received steroids | |||||||
Cummings et al 37 | 1989 | Yes | 0.5 (3), 0.3 (3), then ↓ by 10% every 3 days until 0.1 and then on alternate days for 1 week | 42 | 14 d | 36 | <1250 g; <30 w; MV at 14 days; randomised to three groups, 42 d, 18 d, and control | |||||||
18 |
Figures in parentheses indicate days. PMA = post menstrual age; dex = dexamethasone.